Attached files

file filename
10-K - OGXI-10K-20161231 - ACHIEVE LIFE SCIENCES, INC.ogxi-10k_20161231.htm
EX-32.1 - EX-32.1 - ACHIEVE LIFE SCIENCES, INC.ogxi-ex321_6.htm
EX-31.2 - EX-31.2 - ACHIEVE LIFE SCIENCES, INC.ogxi-ex312_10.htm
EX-31.1 - EX-31.1 - ACHIEVE LIFE SCIENCES, INC.ogxi-ex311_11.htm
EX-23.1 - EX-23.1 - ACHIEVE LIFE SCIENCES, INC.ogxi-ex231_666.htm
EX-21.1 - EX-21.1 - ACHIEVE LIFE SCIENCES, INC.ogxi-ex211_9.htm

Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, John Bencich, Chief Financial Officer of OncoGenex Pharmaceuticals, Inc. (the “Company”), certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that:

(1) the Annual Report on Form 10-K of the Company for the year ended December 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 23, 2017

 

/s/ JOHN BENCICH

John Bencich

Chief Financial Officer